Myelofibrosis Treatment and Procedures

What Are Stem Cells? A Guide to Regenerative Medicine

Stem cells can develop into many cell types and act as the body’s repair system. They replace or restore damaged tissues, offering new possibilities for treating diseases.

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

Doctors

The Curative versus Palliative Paradigm

The Curative versus Palliative Paradigm
The management of myelofibrosis is a tale of two strategies. On one hand, there is the palliative approach, aimed at controlling symptoms, shrinking the spleen, and improving quality of life without eliminating the disease. This uses pharmacological agents such as JAK inhibitors. On the other hand, there is the curative approach, which relies on regenerative medicine—specifically, Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT). This is the only modality capable of replacing the diseased marrow, resolving the fibrosis, and extending survival indefinitely. The choice between these paths is dictated by the patient’s risk profile, age, and physiological fitness.
Icon LIV Hospital

Allogeneic Stem Cell Transplantation (Allo-HSCT)

Allogeneic Stem Cell Transplantation (Allo-HSCT)

preferred option for older patients (up to age 70-75) or those with comorbidities, which is common in myelofibrosis.

The Procedure: Stem cells are collected from the donor’s blood or marrow and infused into the patient. These cells are home to the marrow space. Over time, the healthy donor stem cells repopulate the marrow. Crucially, as the malignant clone is eliminated, the inflammatory signaling stops, and the body slowly degrades the collagen scar tissue, reversing the fibrosis.

Icon 1 LIV Hospital

Pharmacological Therapy: JAK Inhibitors

Pharmacological Therapy: JAK Inhibitors

For patients who are not transplant candidates, or as a “bridge” to transplant, JAK inhibitors are the cornerstone of treatment.

  • Mechanism: Drugs like Ruxolitinib, Fedratinib, and Pacritinib work by blocking the JAK1 and JAK2 signaling pathways. These pathways are hyperactive in myelofibrosis, driving cell proliferation and cytokine release.
  • Effects: These drugs are highly effective at shrinking the spleen (often by 35% or more) and at dramatically reducing constitutional symptoms such as night sweats, fever, and bone pain. They significantly improve the quality of life. However, they are generally not curative; they do not eliminate the malignant clone, and the fibrosis persists or progresses, though more slowly.

Pre-Transplant Optimization: JAK inhibitors are often used before a stem cell transplant to shrink the spleen and improve the patient’s physical condition (performance status), which enhances post-transplant outcomes.

Icon LIV Hospital

Supportive Care and Symptom Management

Treatment and Procedures img 4 1 LIV Hospital

Managing the consequences of marrow failure is a constant component of care.

  • Anemia Management: Packed red blood cell transfusions are common. Medications such as Danazol (an androgen) or Erythropoiesis-Stimulating Agents (ESAs) may help some patients produce red blood cells. Newer agents, such as Luspatercept, are approved to treat transfusion-dependent anemia in myelofibrosis.
  • Splenectomy: In cases where the spleen becomes massively enlarged, painful, or causes severe cytopenias (by trapping blood cells), surgical removal of the spleen (splenectomy) may be considered. However, this is a high-risk procedure in MF patients due to bleeding and clotting risks and is usually a last resort if drugs fail.

Radiation Therapy: Low-dose radiation can be applied to the spleen to provide temporary relief from pain and bulk. It is also used to treat “extramedullary hematopoietic tumors”—masses of blood cells that form outside the marrow, such as near the spinal cord or lungs, causing compression.

Icon 1 LIV Hospital

Clinical Trials and Emerging Therapies

Treatment and Procedures img 5 1 LIV Hospital

The field is active with research into agents that target the disease beyond the JAK pathway.

  • BET Inhibitors: Bromodomain (BET) inhibitors are being studied to reduce cytokine production and fibrosis.
  • BCL-2 Inhibitors: Drugs like Venetoclax promote apoptosis (cell death) in cancer cells and are being tested in combination with JAK inhibitors.

Antifibrotic Agents: Research is ongoing into drugs that specifically target fibrosis-causing cells (fibroblasts) or the cytokines (such as TGF-beta) that drive scarring, aiming to “clean up” the marrow environment to allow healthy blood production.

30
Years of
Excellence

Trusted Worldwide

With patients from across the globe, we bring over three decades of medical expertise and hospitality to every individual who walks through our doors.  

Book a Free Certified Online Doctor Consultation

Doctors

Table of Contents

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

Doctors

FREQUENTLY ASKED QUESTIONS

Can a transplant be done in older patients?

Yes. Historically, age limits were strict, but with the advent of “Reduced Intensity Conditioning” (RIC) regimens, patients up to age 70, and even 75, can successfully undergo stem cell transplantation if they are physically fit and have good organ function. Biological age is more important than chronological age.

No, JAK inhibitors are not curative. They do not permanently eradicate the leukemia cells or the genetic mutation. Their primary role is to control symptoms, reduce spleen size, and improve quality of life. If the medication is stopped, symptoms and spleen enlargement typically return rapidly.

Splenectomy in myelofibrosis is risky. It carries a high rate of complications, including bleeding, blood clots (thrombosis) in the abdominal veins, and susceptibility to overwhelming infections. Furthermore, after the spleen is removed, the liver may enlarge rapidly to take over blood production (hepatomegaly).

Stopping JAK inhibitors abruptly can lead to a condition called “withdrawal syndrome.” This involves a rapid return of symptoms, sometimes worse than before, including high fever, respiratory distress, and shock-like symptoms. Any discontinuation or dose reduction must be tapered slowly under medical supervision.

No. Radiation is a local treatment. It is used to shrink a painful spleen or to treat a mass of blood cells pressing on a nerve or organ outside the marrow. It does not treat the widespread disease in the bone marrow or improve blood counts; in fact, it can temporarily lower blood counts further.

Spine Hospital of Louisiana

Let's Talk About Your Health

BUT WAIT, THERE'S MORE...

Leave your phone number and our medical team will call you back to discuss your healthcare needs and answer all your questions.

Let's Talk About Your Health

Contact Us to Get Information!

Contact
Your Comparison List (you must select at least 2 packages)